UY33679A - Anticuerpos estables y solubles - Google Patents

Anticuerpos estables y solubles

Info

Publication number
UY33679A
UY33679A UY0001033679A UY33679A UY33679A UY 33679 A UY33679 A UY 33679A UY 0001033679 A UY0001033679 A UY 0001033679A UY 33679 A UY33679 A UY 33679A UY 33679 A UY33679 A UY 33679A
Authority
UY
Uruguay
Prior art keywords
antibodies
stable
methods
soluble antibodies
tnf
Prior art date
Application number
UY0001033679A
Other languages
English (en)
Spanish (es)
Inventor
Urech David
Leonardo Jose Borras
Original Assignee
Esbatech
Alcon Biomedical Res Unit Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44897558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33679(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esbatech, Alcon Biomedical Res Unit Llc filed Critical Esbatech
Publication of UY33679A publication Critical patent/UY33679A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
UY0001033679A 2010-10-22 2011-10-20 Anticuerpos estables y solubles UY33679A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40579810P 2010-10-22 2010-10-22
US201161484749P 2011-05-11 2011-05-11

Publications (1)

Publication Number Publication Date
UY33679A true UY33679A (es) 2012-03-30

Family

ID=44897558

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033679A UY33679A (es) 2010-10-22 2011-10-20 Anticuerpos estables y solubles

Country Status (21)

Country Link
US (3) US8545849B2 (cg-RX-API-DMAC7.html)
EP (2) EP2630159B1 (cg-RX-API-DMAC7.html)
JP (4) JP6245985B2 (cg-RX-API-DMAC7.html)
KR (4) KR20190016137A (cg-RX-API-DMAC7.html)
CN (2) CN108359012B (cg-RX-API-DMAC7.html)
AR (1) AR083495A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011318179B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013010949B1 (cg-RX-API-DMAC7.html)
CA (1) CA2814766C (cg-RX-API-DMAC7.html)
CL (2) CL2013001089A1 (cg-RX-API-DMAC7.html)
CO (1) CO6741152A2 (cg-RX-API-DMAC7.html)
CY (1) CY1119941T1 (cg-RX-API-DMAC7.html)
MX (2) MX351499B (cg-RX-API-DMAC7.html)
PH (1) PH12013500675B1 (cg-RX-API-DMAC7.html)
PL (1) PL2630159T3 (cg-RX-API-DMAC7.html)
RU (2) RU2015119440A (cg-RX-API-DMAC7.html)
TW (3) TWI584816B (cg-RX-API-DMAC7.html)
UA (1) UA111340C2 (cg-RX-API-DMAC7.html)
UY (1) UY33679A (cg-RX-API-DMAC7.html)
WO (1) WO2012051734A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201302537B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2752428T1 (sl) * 2008-06-25 2020-03-31 Novartis Ag Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
AR083495A1 (es) * 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
EP2768855B1 (en) * 2011-10-20 2018-06-13 ESBATech - a Novartis Company LLC Stable multiple antigen-binding antibody
EP2809344B1 (en) * 2012-02-02 2016-08-24 ESBATech - a Novartis Company LLC Antibody-containing sustained-release formulation for ocular administration
AU2013290424B2 (en) * 2012-07-19 2018-01-25 Redwood Bioscience, Inc. Antibody specific for CD22 and methods of use thereof
EP2935589A1 (en) 2012-12-18 2015-10-28 Novartis AG Compositions and methods that utilize a peptide tag that binds to hyaluronan
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
BR112017008125B1 (pt) 2014-10-23 2023-11-21 Amgen Inc. Método para a redução da viscosidade de formulações farmacêuticas, formulações farmacêuticas, método de preparação de um pó liofilizado, pó liofilizado e método para reconstituição de um pó liofilizado
PE20181300A1 (es) 2015-11-02 2018-08-09 Five Prime Therapeutics Inc Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer
US12102689B2 (en) 2015-11-09 2024-10-01 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
US12146187B2 (en) 2016-06-20 2024-11-19 Novartis Ag Methods of treating dry eye disease using TNF alpha antagonists
US11059908B2 (en) 2016-09-29 2021-07-13 Amgen Inc. Low-viscosity antigen binding proteins and methods of making them
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
WO2021005607A1 (en) * 2019-07-09 2021-01-14 National Institute For Biotechnology In The Negev Ltd. Antibodies with reduced immunogenicity
CN112786101B (zh) * 2019-11-07 2024-11-12 中国农业大学 热稳定性抗体的制备方法
WO2021102131A1 (en) * 2019-11-21 2021-05-27 Brown University Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5644034A (en) 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE920716A1 (en) 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5213656A (en) 1991-12-04 1993-05-25 Gerber Scientific Products, Inc. Method of using a web for etching of a surface
JPH07502753A (ja) * 1992-07-13 1995-03-23 ユーカリオン，インコーポレイティド 脂質化タンパク質類の血管通過輸送および細胞内輸送
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
EP0614984B2 (en) 1993-03-05 2010-11-03 Bayer HealthCare LLC Anti-TNF alpha human monoclonal antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
PT659439E (pt) 1993-12-24 2002-04-29 Merck Patent Gmbh Imunoconjugados
DE4425115A1 (de) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO1997029131A1 (en) 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
WO1998002462A1 (en) 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
US6470213B1 (en) 1999-03-30 2002-10-22 Kenneth A. Alley Implantable medical device
AU768827B2 (en) 1999-12-28 2004-01-08 Esbatech, An Alcon Biomedical Research Unit Llc Intrabodies with defined framework that is stable in a reducing environment and applications thereof
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
SG97908A1 (en) 2000-08-03 2003-08-20 Inst Data Storage A method and apparatus for load/unload testing of disk drives
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
DK1506236T3 (da) 2002-05-22 2013-03-04 Esbatech A Novartis Co Llc Immunglobulin-frameworks, der udviser forbedret stabilitet i det intracellulære miljø og fremgangsmåder til identifikation deraf
EP1539947A4 (en) 2002-08-15 2006-09-06 Epitomics Inc HUMANIZED RABBIT ANTIBODIES
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP1613946A4 (en) 2003-03-20 2006-07-12 Univ Northeastern Ohio INCLUDED TEST DEVICE FOR FAST DETECTION OF BIOLOGICAL CONTAMINANTS
DE10314412A1 (de) 2003-03-28 2004-10-14 Genovac Ag Genetische Immunisierung mit multiplen Expressionskonstrukten zur Herstellung von monoklonalen Antikörpern
US20050048578A1 (en) 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
JP2007520991A (ja) 2003-08-07 2007-08-02 エピトミクス インコーポレーティッド ウサギ単クローン抗体をヒト型化する方法
CA2537055A1 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US20080003617A1 (en) 2004-12-20 2008-01-03 Xiaomin Fan Methods for the identification and the isolation of epitope specific antibodies
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
ES2424042T3 (es) 2005-06-07 2013-09-26 Esbatech - A Novartis Company Llc Anticuerpos estables y solubles que inhiben TNF±
DK2135881T3 (da) 2005-06-20 2011-12-05 Genentech Inc Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
GB0520436D0 (en) 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
AU2006300951A1 (en) 2005-10-11 2007-04-19 Domantis Limited Antibody polypeptide library screening and selected antibody polypeptides
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
MX2008011874A (es) * 2006-03-17 2009-01-07 Biogen Idec Inc Composiciones estabilizadas de polipeptidos.
JP5431920B2 (ja) 2006-04-28 2014-03-05 デリネックス・セラピューティクス・アーゲー 受容体チロシンキナーゼａｌｋの細胞外ドメインに結合する抗体
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
LT2046382T (lt) 2006-07-10 2016-12-12 Esbatech, An Alcon Biomedical Research Unit Llc Scfv antikūnai, pereinantys epitelio ir (arba) endotelio sluoksnius
NZ613356A (en) 2006-10-27 2015-02-27 Abbvie Biotechnology Ltd Crystalline anti-htnfalpha antibodies
US20100111963A1 (en) 2006-11-10 2010-05-06 Genentech, Inc. Method for treating age-related macular degeneration
JP5622397B2 (ja) 2007-03-12 2014-11-12 エスバテック− ア ノバルティス カンパニー エルエルシー 一本鎖抗体の配列に基づく操作および最適化
EP2162469A4 (en) 2007-05-21 2012-08-01 Alderbio Holdings Llc NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES
SI2164961T1 (sl) * 2007-06-25 2015-05-29 Esbatech, An Alcon Biomedical Research Unit Llc InĹľeniring na osnovi zaporedij in optimizacija mono-veriĹľnih protiteles
HRP20160730T1 (hr) * 2007-06-25 2016-07-15 Esbatech, An Alcon Biomedical Research Unit Llc Metode modificiranja antitijela i modificirana antitijela s poboljšanim funkcionalnim svojstvima
WO2009052140A1 (en) * 2007-10-15 2009-04-23 Alcon Research, Ltd. Use of tnf receptor antagonists for treating dry eye
CA2710779C (en) * 2007-12-31 2017-06-20 Bayer Schering Pharma Aktiengesellschaft Antibodies to tnf.alpha.
SI3722310T1 (sl) 2008-06-25 2025-01-31 Novartis Ag Stabilna in topna protitelesa, ki zavirajo vegf
ES2687259T5 (es) * 2008-06-25 2022-10-14 Novartis Ag Anticuerpos estables y solubles que inhiben TNF
WO2009155725A1 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
SI2752428T1 (sl) 2008-06-25 2020-03-31 Novartis Ag Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
RU2016108598A (ru) 2008-06-30 2018-11-23 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Функционализированные полипептиды
EP2303230A2 (en) 2008-07-10 2011-04-06 ESBATech, an Alcon Biomedical Research Unit LLC Methods and compositions for enhanced delivery of macromolecules
CA2758964A1 (en) 2009-04-16 2010-10-21 Abbott Biotherapeutics Corp. Anti-tnf-.alpha. antibodies and their uses
RU2585534C2 (ru) 2009-12-23 2016-05-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Способ снижения иммуногенности
CA2804964C (en) 2010-07-15 2016-06-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
AR083495A1 (es) * 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
SG191712A1 (en) 2010-11-02 2013-08-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
HK1200321A1 (en) 2011-10-24 2015-08-07 Abbvie Inc. Bispecific immunobinders directed against tnf and il-17
UY34409A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoenlazadores dirigidos contra el tnf

Also Published As

Publication number Publication date
EP2630159A1 (en) 2013-08-28
JP6245985B2 (ja) 2017-12-13
KR20160083970A (ko) 2016-07-12
KR101635917B1 (ko) 2016-07-04
CL2015002735A1 (es) 2016-03-04
KR20170020558A (ko) 2017-02-22
CN108359012B (zh) 2021-12-24
RU2015119440A (ru) 2015-11-27
EP3336105A1 (en) 2018-06-20
CA2814766C (en) 2017-11-28
JP7148228B2 (ja) 2022-10-05
RU2013123266A (ru) 2014-11-27
MX351499B (es) 2017-10-17
AU2011318179B2 (en) 2014-12-11
US9598487B2 (en) 2017-03-21
PH12013500675A1 (cg-RX-API-DMAC7.html) 2013-06-10
BR112013010949B1 (pt) 2022-02-01
RU2558298C2 (ru) 2015-07-27
BR112013010949A2 (cg-RX-API-DMAC7.html) 2017-09-05
JP2017184770A (ja) 2017-10-12
JP2019054814A (ja) 2019-04-11
CO6741152A2 (es) 2013-08-30
CN103154033A (zh) 2013-06-12
PH12013500675B1 (en) 2017-09-06
AU2011318179A1 (en) 2013-05-02
EP2630159B1 (en) 2017-11-22
TWI584816B (zh) 2017-06-01
KR20190016137A (ko) 2019-02-15
WO2012051734A1 (en) 2012-04-26
CN108359012A (zh) 2018-08-03
TWI652068B (zh) 2019-03-01
RU2015119440A3 (cg-RX-API-DMAC7.html) 2019-01-28
CL2013001089A1 (es) 2014-03-07
US20130344086A1 (en) 2013-12-26
CA2814766A1 (en) 2012-04-26
US20160176959A1 (en) 2016-06-23
UA111340C2 (uk) 2016-04-25
US8545849B2 (en) 2013-10-01
PL2630159T3 (pl) 2018-04-30
MX2013004295A (es) 2013-06-05
JP2015193664A (ja) 2015-11-05
US20120100153A1 (en) 2012-04-26
TWI702230B (zh) 2020-08-21
TW201630623A (zh) 2016-09-01
KR101947520B1 (ko) 2019-02-14
ZA201302537B (en) 2014-06-25
JP2013544078A (ja) 2013-12-12
KR20130138806A (ko) 2013-12-19
US10570198B2 (en) 2020-02-25
TW201221142A (en) 2012-06-01
CN103154033B (zh) 2018-04-24
AR083495A1 (es) 2013-02-27
CY1119941T1 (el) 2018-12-12
TW201920270A (zh) 2019-06-01
EP3336105B1 (en) 2020-11-04

Similar Documents

Publication Publication Date Title
UY33679A (es) Anticuerpos estables y solubles
CY1123978T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν ton tnf
CY1119925T1 (el) Aνti-cd40 αντισωματα, χρησεις και μεθοδοι
MX2020012744A (es) Metodo y composiciones para inmunoterapia celular.
CU20200089A7 (es) Moléculas de unión contra bcma
MX366965B (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
NZ706377A (en) Il-6 antagonists and uses thereof
MX391041B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
MX2011000011A (es) Anticuerpos estables y solubles que inhiben el vegf.
AR070453A1 (es) Anticuerpos dirigidos a angiopoyetina -1 y angiopoyetina-2 y usos de los mismos
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
CO6680693A2 (es) Anticuerpos humanos recombinantes, tanto humanizados como quiméricos, los cuales en lazan especificamente a ox40 humano
AR073775A1 (es) Anticuerpos biespecificos anti-vegf/anti- ang -2
AR067666A1 (es) Proteinas de union al antigeno del receptor de il-18
CO7250445A2 (es) Proteínas de unión a antígeno st2
CL2021003050A1 (es) Moléculas de unión a cd19 y usos de las mismas
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
PE20170779A1 (es) Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos
CL2015001507A1 (es) Proteínas de unión al antígeno bcma
MX2007015280A (es) Anticuerpos estables y solubles que inhiben tnf-alfa.
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
CR20120404A (es) Proteinas de enlace cd127
AR088512A1 (es) Anticuerpos dirigidos contra el tnf
BR112015018203A2 (pt) Anti-corpos biespecíficos anti-tnf-anti-il-17
MX355759B (es) Peptidos topk y vacunas que incluyen los mismos.

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20211028